Skip to Content

News & Events

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment
-Results support continued development of VX-765 in people with treatment-resistant epilepsy- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a recently completed Phase 2 study of VX-765 in 60 people with treatment-resistant
View HTML
Toggle Summary Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education
- Vertex commits more than $1 million to support education for BPS students and to prepare teachers for new science education standards- -Company dedicates 3,000 square foot learning laboratory at new Fan Pier headquarters to local community- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals
View HTML
Toggle Summary Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C
-Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and Janssen's investigational protease inhibitor simeprevir (TMC435)- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment
HCV
View HTML
Toggle Summary Vertex Announces CEO Succession Plan for 2012
- Jeffrey Leiden , M.D., Ph.D., to become CEO in February 2012 - - Matthew Emmens elects to retire in May; will remain director for Vertex Board- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has appointed Jeffrey
View HTML
Toggle Summary Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference . Following implementation of a companywide travel and meetings policy that is designed to reduce
View HTML
Toggle Summary Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand
LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO ® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1 . Clinicians are able to apply for patient access using the
View HTML
Toggle Summary Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia
- CASGEVY™ is first medicine ever to be evaluated through the SFDA’s Breakthrough Medicines Program - - First treatment center in Saudi Arabia has been activated - BOSTON --(BUSINESS WIRE)--Jan. 9, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Saudi Food and
View HTML
Toggle Summary Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at
View HTML
Toggle Summary Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development
BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz , M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the
View HTML
Toggle Summary Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines
-Eligible patients in England will have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with
View HTML